Free Trial

IQVIA (IQV) Stock Forecast & Price Target

$214.63
+2.92 (+1.38%)
(As of 10/25/2024 ET)

IQVIA - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Sell
0
Hold
4
Buy
13

Based on 17 Wall Street analysts who have issued ratings for IQVIA in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 17 analysts, 4 have given a hold rating, 12 have given a buy rating, and 1 has given a strong buy rating for IQV.

Consensus Price Target

$267.27
24.52% Upside
According to the 17 analysts' twelve-month price targets for IQVIA, the average price target is $267.27. The highest price target for IQV is $300.00, while the lowest price target for IQV is $220.00. The average price target represents a forecasted upside of 24.52% from the current price of $214.63.
Get the Latest News and Ratings for IQV and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for IQVIA and its competitors.

Sign Up

IQV Analyst Ratings Over Time

TypeCurrent Forecast
10/27/23 to 10/26/24
1 Month Ago
9/27/23 to 9/26/24
3 Months Ago
7/29/23 to 7/28/24
1 Year Ago
10/27/22 to 10/27/23
Strong Buy
1 Strong Buy rating(s)
1 Strong Buy rating(s)
1 Strong Buy rating(s)
1 Strong Buy rating(s)
Buy
12 Buy rating(s)
12 Buy rating(s)
12 Buy rating(s)
12 Buy rating(s)
Hold
4 Hold rating(s)
4 Hold rating(s)
4 Hold rating(s)
4 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$267.27$267.27$267.27$267.27
Forecasted Upside24.52% Upside24.52% Upside24.52% Upside24.52% Upside
Consensus Rating
Moderate Buy
Moderate Buy
Moderate Buy
Moderate Buy

IQV Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

IQV Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

IQVIA Stock vs. The Competition

TypeIQVIAMedical CompaniesS&P 500
Consensus Rating Score
2.82
2.79
2.50
Consensus RatingModerate BuyModerate BuyHold
Predicted Upside24.52% Upside7,915.51% Upside9.04% Upside
News Sentiment Rating
Positive News

See Recent IQV News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
10/23/2024JPMorgan Chase & Co.
3 of 5 stars
 Lower TargetOverweight ➝ Overweight$288.00 ➝ $279.00+22.21%
10/15/2024Barclays
3 of 5 stars
 Lower TargetOverweight ➝ Overweight$275.00 ➝ $260.00+11.49%
10/14/2024Truist Financial
2 of 5 stars
 Lower TargetBuy ➝ Buy$300.00 ➝ $286.00+24.61%
10/14/2024Redburn Atlantic
Subscribe to MarketBeat All Access for the recommendation accuracy rating
J. Clark
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$276.00+20.32%
10/8/2024Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOutperform ➝ Outperform$270.00 ➝ $265.00+17.33%
9/20/2024Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetNeutral ➝ Neutral$251.00 ➝ $256.00+4.65%
9/4/2024Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
S. Dodge
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$275.00+10.57%
7/31/2024Argus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
D. Toung
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
7/24/2024Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeBuy ➝ Hold$266.00 ➝ $242.00+1.34%
7/23/2024Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOverweight ➝ Overweight$270.00 ➝ $280.00+16.57%
7/23/2024UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$295.00 ➝ $300.00+24.28%
6/6/2024The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$270.00+23.30%
2/26/2024Leerink Partnrs
Subscribe to MarketBeat All Access for the recommendation accuracy rating
S. Davis
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform
2/26/2024Leerink Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOutperform$290.00+17.29%
2/15/2024Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeBuy ➝ Neutral
2/13/2024BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$285.00+30.81%
12/11/2023Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetNeutral ➝ Neutral$190.00 ➝ $225.00+4.52%
10/10/2023Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy ➝ Buy$250.00 ➝ $229.00+14.76%
9/6/2023HSBC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$260.00+17.71%
8/2/2023Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$255.00 ➝ $281.00+28.44%
5/1/2023Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower Target$235.00 ➝ $220.00+16.88%
2/13/2023Credit Suisse Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOutperform$265.00+14.17%
12/6/2022Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOutperform$251.00+18.44%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 08:18 AM ET.


Should I Buy IQVIA Stock? IQV Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Friday, October 18, 2024. Please send any questions or comments about these IQVIA pros and cons to contact@marketbeat.com.

IQVIA
Bull Case

green Wall Street bull icon

Here are some ways that investors could benefit from investing in IQVIA Holdings Inc.:

  • IQVIA Holdings Inc. has shown consistent revenue growth over recent quarters, indicating a strong financial performance.
  • Analysts have been upgrading their price targets for IQVIA Holdings Inc., suggesting positive sentiment and potential for stock price appreciation.
  • IQVIA Holdings Inc. reported earnings per share (EPS) that exceeded analysts' estimates, demonstrating strong profitability.
  • The company's stock price has been trending upwards, showing positive momentum in the market.
  • IQVIA Holdings Inc. has a diverse range of services in advanced analytics, technology solutions, and clinical research, providing stability and growth potential in the life sciences industry.

IQVIA
Bear Case

red Wall Street bear icon

Investors should be bearish about investing in IQVIA Holdings Inc. for these reasons:

  • The stock's current price may be considered high based on its historical valuation metrics, potentially limiting short-term upside.
  • There could be regulatory risks associated with the healthcare and life sciences industry that may impact IQVIA Holdings Inc.'s operations and profitability.
  • Competition in the industry from other research and analytics companies could pose a challenge to IQVIA Holdings Inc.'s market share and growth prospects.
  • Market volatility and economic uncertainties may affect the demand for IQVIA Holdings Inc.'s services, leading to fluctuations in revenue and stock performance.
  • IQVIA Holdings Inc.'s debt-to-equity ratio of 1.80 may raise concerns about the company's leverage and financial stability in changing market conditions.

IQV Forecast - Frequently Asked Questions

According to the research reports of 17 Wall Street equities research analysts, the average twelve-month stock price forecast for IQVIA is $267.27, with a high forecast of $300.00 and a low forecast of $220.00.

17 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for IQVIA in the last twelve months. There are currently 4 hold ratings, 12 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" IQV shares.

According to analysts, IQVIA's stock has a predicted upside of 24.52% based on their 12-month stock forecasts.

Over the previous 90 days, IQVIA's stock had 1 upgrade by analysts.

IQVIA has been rated by research analysts at Argus, Barclays, Evercore ISI, JPMorgan Chase & Co., Redburn Atlantic, Robert W. Baird, Royal Bank of Canada, and Truist Financial in the past 90 days.

Analysts like IQVIA more than other "medical" companies. The consensus rating score for IQVIA is 2.82 while the average consensus rating score for "medical" companies is 2.79. Learn more on how IQV compares to other companies.


This page (NYSE:IQV) was last updated on 10/26/2024 by MarketBeat.com Staff
From Our Partners